Affini-T Therapeutics
Dirigeants
Voir l'organigramme avec ses 12 principaux dirigeants
Biographies les plus recherchées chez Affini-T Therapeutics
- Jak Knowles, Co-Founder, President, Chief Executive Officer and D...
- Lucio Iannone, Director
- Arjun Goyal, Director
Changements de dirigeants chez Affini-T Therapeutics
- Kathy Bergsteinsson, a rejoint l'entreprise comme Chief Financial Officer (publié le 14 novembre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Affini-T Therapeutics.
Biotechnologie
Affini-T Therapeutics a 2 292 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Lycia Therapeutics vient d'annoncer une levée de fonds de 107 millions de dollars. (publié le 15 mai 2024).
- Attovia Therapeutics vient d'annoncer une levée de fonds de 150 millions de dollars. (publié le 14 mai 2024).
- Bruker has announced the acquisition of NanoString Technologies (publié le 13 mai 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Affini-T Therapeutics
- Affini-T Therapeutics to Present Data from Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Affini-T Therapeutics
- Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Affini-T Therapeutics
- Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer | Affini-T Therapeutics
- Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
- Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
- A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Affini-T Therapeutics
- Affini-T Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Affini-T Therapeutics sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Jak Knowles 
Appelez Affini-T Therapeutics au +1 619...
